美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Palvella Therapeutics

136.70

+2.311.72%

盤後：136.700.00000.00%18:00 EDT

成交量：25.86萬

成交額：3,509.84萬

市值：18.37億

市盈率：-38.73

高：138.89

開：132.14

低：130.50

收：134.39

52周最高：151.18

52周最低：18.23

股本：1,343.65萬

流通股本：839.81萬

量比：0.92

換手率：3.08%

股息：- -

股息率：- -

每股收益(TTM):-3.5291

每股收益(LYR):-7.8322

淨資產收益率：-301.19%

總資產收益率：-47.54%

市淨率：47.48

市盈率(LYR):-17.45

資料載入中...

總覽公司新聞資訊公告

BUZZ-Palvella Therapeutics 增發 2 億美元后持續大漲

Palvella Therapeutics宣佈啓動1.5億美元公開發行計劃

BUZZ--美國股票走勢-Henry Schein、多米諾比薩、FactSet

Palvella Therapeutics股價盤前飆升23%，其皮膚病藥物達成後期試驗目標

BUZZ-罕見病治療在後期研究中取得進展，Palvella公司業績大增

Palvella Therapeutics在預設關鍵次要終點及全部四項次要療效終點均達到統計學顯著性（所有P值均小於0.001）

Palvella Therapeutics公布Qtorin™ 3.9%雷帕黴素無水凝膠治療微囊型淋巴管畸形三期Selva臨床研究積極頂線結果

Palvella Therapeutics計劃於2026年下半年向FDA提交新藥申請

Palvella Therapeutics將召開電話會議討論Qtorin™雷帕黴素無水凝膠治療微囊型淋巴管畸形三期臨床試驗關鍵結果

Palvella Therapeutics, Inc.盤中異動下午盤急速拉升5.35%

Palvella Therapeutics, Inc.盤中異動股價大漲5.03%

Palvella Therapeutics發布公司進展與2026年展望：推進後期臨床階段管線，以平台化策略攻克無FDA批准療法的嚴重罕見皮膚病及血管畸形

BUZZ-Palvella Therapeutics 在 Truist 上調預期薪酬後攀升

Palvella Therapeutics 獲得 FDA 快速通道認證，用於治療血管角化瘤的 Qtorin™ 3.9% 乾燥雷帕黴素凝膠 (Qtorin™ Rapamycin)

Palvella Therapeutics公布Qtorin™ 3.9%無水雷帕黴素凝膠（Qtorin™ Rapamycin）治療皮膚靜脈畸形的二期Toiva臨床試驗積極頂線結果

Palvella Therapeutics股價上漲11.2%，因Raymond James將評級從「跑贏大盤」上調至「強烈買入」

Palvella Therapeutics發布2025年第三季度財務業績並提供公司更新

Palvella Therapeutics：Raymond James將評級上調至強力買入，目標價格由92美元提高至143美元

Palvella Therapeutics 宣佈推出 Qtorin™ 新產品候選者 Qtorin™ Pitavastatin，用於治療一種罕見的慢性前癌性遺傳皮膚疾病——擴散性淺表性光敏性角化病（Dsap），該疾病尚無 FDA 批准的治療方案

美國食品藥品監督管理局授予Palvella Therapeutics孤兒產品資助第二年資金，支持Qtorin™雷帕黴素治療微囊性淋巴管畸形的三期Selva試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PVLA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":136.7,"timestamp":1773086400000,"preClose":134.39,"halted":0,"volume":258607,"hourTrading":{"tag":"盘后","latestPrice":136.7,"preClose":136.7,"latestTime":"18:00 EDT","volume":4437,"amount":606533.0636700001,"timestamp":1773093622834,"change":0,"changeRate":0,"amplitude":0.00278},"delay":0,"changeRate":0.017188778927003517,"floatShares":8398100,"shares":13436500,"eps":-3.529122,"marketStatus":"盤後交易","change":2.31,"latestTime":"03-09 18:38:31 EDT","open":132.14,"high":138.89,"low":130.5,"amount":35098359.269880004,"amplitude":0.06243,"askPrice":142.5,"askSize":7,"bidPrice":136.7,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1773100800000},"marketStatusCode":4,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":134.39,"postHourTrading":{"tag":"盘后","latestPrice":136.7,"preClose":136.7,"latestTime":"18:00 EDT","volume":4437,"amount":606533.0636700001,"timestamp":1773093622834,"change":0,"changeRate":0,"amplitude":0.00278},"volumeRatio":0.915054,"impliedVol":0.8597,"impliedVolPercentile":0.8526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-47.54%","roe":"-301.19%","lyrEps":-7.832217,"volumeRatio":0.915054,"shares":13436500,"dividePrice":0,"high":138.89,"amplitude":0.06243,"preClose":134.39,"low":130.5,"week52Low":18.225,"pbRate":"47.48","week52High":151.18,"institutionHeld":0,"latestPrice":136.7,"committee":-0.166667,"eps":-3.529122,"divideRate":0,"volume":258607,"delay":0,"ttmEps":-3.529122,"open":132.14,"prevYearClose":104.67,"prevWeekClose":134.39,"prevMonthClose":135.02,"prevQuarterClose":104.67,"fiveDayClose":132.61,"twentyDayClose":82.2,"sixtyDayClose":98.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"盤前","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1767848400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-03-06","current":-38.734847,"percent":0.009868,"low":-60.48704,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"high":46.119317,"avg":-11.762389,"sd":24.228882,"marketCap":1813254325},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325}],"updateTime":1773087988107},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614047174","title":"BUZZ-Palvella Therapeutics 增發 2 億美元后持續大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2614047174","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614047174?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 21:50","pubTimestamp":1772113816,"startTime":"0","endTime":"0","summary":"** Palvella Therapeutics PVLA.O股价在盘前上涨9.6%至140.96美元，创三年新高，此前该公司已完成2亿美元的增发。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL4S3ZM1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4139","BK4127","PVLA"],"gpt_icon":0},{"id":"1131097658","title":"Palvella Therapeutics宣佈啓動1.5億美元公開發行計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1131097658","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131097658?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 05:13","pubTimestamp":1771967581,"startTime":"0","endTime":"0","summary":"2026年2月24日，临床阶段生物制药公司Palvella Therapeutics正式启动承销式公开发行，拟募集1.5亿美元普通股。该公司专注于针对罕见严重皮肤病及血管畸形领域研发创新疗法，这些疾病目前均未获得美国FDA批准的治疗方案。本次发行所有股份均由Palvella提供，最终规模取决于市场环境及监管条件，存在不确定性。此次发行的联合账簿管理人为TD Cowen、Cantor、Stifel、Mizuho等八家机构，Lucid Capital Markets等四家机构担任联席经理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","TM","03160","PVLA","BK4604","BK4588","USA","BK4585","BK4139","BK4555"],"gpt_icon":0},{"id":"2614874530","title":"BUZZ--美國股票走勢-Henry Schein、多米諾比薩、FactSet","url":"https://stock-news.laohu8.com/highlight/detail?id=2614874530","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614874530?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 00:00","pubTimestamp":1771948829,"startTime":"0","endTime":"0","summary":"nL6N3ZK0S4 ** Kratos Defense & Security Solutions Inc KTOS.O:BUZZ - 在第一季度营收预测低于预期后下跌 nL6N3ZK0RG ** AES Corp AES.N:BUZZ - 谷歌数据中心交易后上涨   nL6N3ZK0S8 ** PPL Corp PPL.N:BUZZ--在公用事业公司出售 10 亿美元股票单位、华尔街评级提升后上涨   nL6N3ZK0SJ ** Construction Partners Inc ROAD.O:BUZZ - 由于运营实力强劲，美国银行上调了Construction Partners的PT。nL4N3ZK13K ** Larimar Therapeutics Inc LRMR.O:BUZZ - 因美国食品及药物管理局为神经系统疾病疗法贴上 \"突破性 \"标签而大涨   nL4N3ZK19H ** Consolidated Edison Inc ED.N:BUZZ - 因发行 7.77 亿美元股票而下跌   nL6N3ZK0WF ** Protara Therapeutics Inc TARA.O:BUZZ - 因癌症药物数据低于投资者预期而下跌   nL4N3ZK1CT ** Henry Schein Inc HSIC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4T3ZK1LZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AWI","TARA","ELAN","THR","WHR","ANPA","BOOM","CLVT","AMDW","AU","PPL","VIR","KEYS","LRMR","NWMX","OKE","ROAD","NRG","AES","ITRI","CVS","KTOS","EXPD","TNC","FDS","ED","AMYY","CNP","ELIS","ELIL","HSIC","FRPT","DPZ","SHLS","HD","OWL","LLII","LLYZ","SEG","PVLA","FGL","ALUR","KDP"],"gpt_icon":1},{"id":"1185545003","title":"Palvella Therapeutics股價盤前飆升23%，其皮膚病藥物達成後期試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=1185545003","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185545003?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 20:55","pubTimestamp":1771937734,"startTime":"0","endTime":"0","summary":"在宣布其针对罕见皮肤病的研究药物成功达成一项关键后期试验的主要目标后，Palvella Therapeutics的股价在盘前交易中大幅上涨了23%。这一积极结果极大地提振了投资者信心，预示着该疗法在寻求监管批准的道路上迈出了关键一步。该公司的前景因此次试验成功而显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613788719","title":"BUZZ-罕見病治療在後期研究中取得進展，Palvella公司業績大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2613788719","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613788719?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 20:49","pubTimestamp":1771937393,"startTime":"0","endTime":"0","summary":"我们认为，就 Qtorin 适应症的总体市场机会而言，Palvella 的股价仍被大幅低估。** Palvella 计划在 2026 年下半年向美国 FDA 提交上市申请，预计可能在 2027 年上半年获得批准。** 股价年初至今下跌了 16.1% (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4S3ZK159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1198934231","title":"Palvella Therapeutics在預設關鍵次要終點及全部四項次要療效終點均達到統計學顯著性（所有P值均小於0.001）","url":"https://stock-news.laohu8.com/highlight/detail?id=1198934231","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198934231?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:33","pubTimestamp":1771932795,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics宣布，其临床研究在预设的关键次要终点上取得了统计学显著性结果，P值小于0.001。此外，该研究还成功在所有四项次要疗效终点上均显示出统计学显著性，所有P值同样低于0.001。\n这一系列积极数据进一步验证了该公司在研疗法的有效性与可靠性，为后续研发及监管申报提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1169232983","title":"Palvella Therapeutics公布Qtorin™ 3.9%雷帕黴素無水凝膠治療微囊型淋巴管畸形三期Selva臨床研究積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1169232983","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169232983?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:32","pubTimestamp":1771932736,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公司宣布，其针对微囊型淋巴管畸形（Microcystic Lymphatic Malformations）的候选药物Qtorin™ 3.9%雷帕霉素无水凝胶（Qtorin™ Rapamycin），在三期Selva临床研究中取得了积极的顶线结果。\n该研究成功达到了其主要疗效终点，显示出具有高度统计学显著性和临床意义的改善。安全性数据与药物已知的安全性特征一致，未发现新的安全信号。\n这一积极数据是推动该疗法向监管提交申请的关键一步，为患有这种罕见疾病的患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1161160003","title":"Palvella Therapeutics計劃於2026年下半年向FDA提交新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1161160003","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161160003?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 19:31","pubTimestamp":1771932675,"startTime":"0","endTime":"0","summary":"生物制药公司Palvella Therapeutics Inc (PVLA) 近日公布了其关键药物的最新进展。根据公司规划，Palvella预计将在2026年下半年向美国食品药品监督管理局（FDA）正式提交新药申请（NDA）。这一时间表的公布，标志着该公司核心研发项目进入了重要的冲刺阶段，为后续的商业化进程奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1144468815","title":"Palvella Therapeutics將召開電話會議 討論Qtorin™雷帕黴素無水凝膠治療微囊型淋巴管畸形三期臨床試驗關鍵結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1144468815","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144468815?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884016,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布将举办专题电话会议，重点解读其候选药物Qtorin™ 3.9%雷帕霉素无水凝胶（Qtorin™ Rapamycin）针对微囊型淋巴管畸形适应症的三期Selva临床试验的顶线结果。此次会议将深入探讨该试验的核心数据及其潜在临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2612255671","title":"Palvella Therapeutics, Inc.盤中異動 下午盤急速拉升5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612255671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612255671?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 03:23","pubTimestamp":1771529003,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日03时23分，Palvella Therapeutics, Inc.股票出现异动，股价急速上涨5.35%。Palvella Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。Palvella Therapeutics, Inc.公司简介：Palvella Therapeutics Inc 是一家晚期临床阶段的生物制药公司，致力于为那些患有严重的、罕见的遗传皮肤病的患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022003232495417a00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022003232495417a00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","BK4539","PVLA"],"gpt_icon":0},{"id":"2606894223","title":"Palvella Therapeutics, Inc.盤中異動 股價大漲5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606894223","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606894223?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 23:07","pubTimestamp":1769440063,"startTime":"0","endTime":"0","summary":"北京时间2026年01月26日23时07分，Palvella Therapeutics, Inc.股票出现异动，股价大幅拉升5.03%。Palvella Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.54%。其相关个股中，Seastar Medical Holding Corp C/Wts 28/10/2027 、Acumen Pharmaceuticals, Inc.、Cel-Sci Corporation涨幅较大，Revelation Biosciences, Inc.、60 Degrees Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.较为活跃，换手率分别为54.65%、40.57%、29.96%，振幅较大的相关个股有Acumen Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Novabay Pharmaceuticals, Inc.，振幅分别为41.91%、32.26%、29.75%。Palvella Therapeutics, Inc.公司简介：Palvella Therapeutics Inc 是一家晚期临床阶段的生物制药公司，致力于为那些患有严重的、罕见的遗传皮肤病的患者提供治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126230743953e6b2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126230743953e6b2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PVLA","BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"1134522020","title":"Palvella Therapeutics發布公司進展與2026年展望：推進後期臨床階段管線，以平台化策略攻克無FDA批准療法的嚴重罕見皮膚病及血管畸形","url":"https://stock-news.laohu8.com/highlight/detail?id=1134522020","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134522020?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 20:30","pubTimestamp":1767961814,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics近期披露了公司最新动态及面向2026年的战略规划。该公司正全力推进其处于后期临床阶段的产品管线与技术平台，致力于解决目前尚无美国食品药品监督管理局（FDA）批准疗法的多种严重罕见皮肤病及血管畸形疾病。这一举措凸显了公司聚焦未满足临床需求的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2592931275","title":"BUZZ-Palvella Therapeutics 在 Truist 上調預期薪酬後攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931275","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931275?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 02:38","pubTimestamp":1765910315,"startTime":"0","endTime":"0","summary":"BUZZ-Palvella Therapeutics 在 Truist 上调预期薪酬后攀升12月16日 - ** 药物开发商Palvella Therapeutics PVLA.O股价上涨6.14%至94.45美元** Truist将目标股价从105美元上调至190美元，较上一交易日上涨113.5%。** Truist称，该公司Qtorin凝胶的小型概念验证研究为皮肤静脉畸形患者提供了充分的 \"去风险 \"机会，皮肤静脉畸形是一种导致静脉功能障碍的罕见遗传性皮肤病。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL4S3XM15O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1132581978","title":"Palvella Therapeutics 獲得 FDA 快速通道認證，用於治療血管角化瘤的 Qtorin™ 3.9% 乾燥雷帕黴素凝膠 (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=1132581978","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132581978?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888255,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 获得 FDA 快速通道认证，用于治疗血管角化瘤的 Qtorin™ 3.9% 干燥雷帕霉素凝胶 (Qtorin™ Rapamycin)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1123205248","title":"Palvella Therapeutics公布Qtorin™ 3.9%無水雷帕黴素凝膠（Qtorin™ Rapamycin）治療皮膚靜脈畸形的二期Toiva臨床試驗積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123205248","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123205248?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 19:01","pubTimestamp":1765796473,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics公布Qtorin™ 3.9%无水雷帕霉素凝胶（Qtorin™ Rapamycin）治疗皮肤静脉畸形的二期Toiva临床试验积极顶线结果。这是一种严重的罕见遗传疾病，目前尚无FDA批准的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1134453895","title":"Palvella Therapeutics股價上漲11.2%，因Raymond James將評級從「跑贏大盤」上調至「強烈買入」","url":"https://stock-news.laohu8.com/highlight/detail?id=1134453895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134453895?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573311,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics股价上涨11.2%，因Raymond James将评级从“跑赢大盘”上调至“强烈买入”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1121184983","title":"Palvella Therapeutics發布2025年第三季度財務業績並提供公司更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121184983?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 01:24","pubTimestamp":1763573099,"startTime":"0","endTime":"0","summary":"11月11日 - Palvella Therapeutics Inc 发表声明：*PALVELLA THERAPEUTICS发布2025年第三季度财务业绩并提供公司更新*PALVELLA THERAPEUTICS INC：第三季度每股收益为-$1.03","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"1156492120","title":"Palvella Therapeutics：Raymond James將評級上調至強力買入，目標價格由92美元提高至143美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156492120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156492120?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 20:12","pubTimestamp":1763554332,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics：Raymond James将评级上调至强力买入，目标价格由92美元提高至143美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1160931524","title":"Palvella Therapeutics 宣佈推出 Qtorin™ 新產品候選者 Qtorin™ Pitavastatin，用於治療一種罕見的慢性前癌性遺傳皮膚疾病——擴散性淺表性光敏性角化病（Dsap），該疾病尚無 FDA 批准的治療方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1160931524","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160931524?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 19:01","pubTimestamp":1762340484,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics 宣布推出 Qtorin™ 新产品候选者 Qtorin™ Pitavastatin，用于治疗一种罕见的慢性前癌性遗传皮肤疾病——扩散性浅表性光敏性角化病（Dsap），该疾病尚无 FDA 批准的治疗方案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"1189215679","title":"美國食品藥品監督管理局授予Palvella Therapeutics孤兒產品資助第二年資金，支持Qtorin™雷帕黴素治療微囊性淋巴管畸形的三期Selva試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1189215679","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189215679?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355015,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局授予Palvella Therapeutics孤儿产品资助第二年资金，用于支持该公司Qtorin™雷帕霉素治疗微囊性淋巴管畸形的三期Selva临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}